Trial Profile
Phase II study for the evaluation of neoadjuvant treatment with cabozantinib prior to cytoreductive nephrectomy in patients with locally advanced or metastatic renal cell carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Mar 2024
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms CABOPRE
- 27 Jan 2024 Results assessing change expression differences of selective mi-RNAs in plasma and TME previous before and after 12 first weeks of perioperatory cabozantinib,presented at the 2024 Genitourinary Cancers Symposium
- 02 Jul 2018 New trial record
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology